Personal stories

A Johnson & Johnson scientist explains how the Acuvue® Oasys Max 1-Day Multifocal for Astigmatism contact lens also filters blue light, supports the eye’s natural tear film and helps eyes easily switch focus from distance to reading.

Once considered a straightforward procedure to restore cloudy vision, cataract surgery has evolved into one of the most technologically advanced—and personalized—operations in modern medicine. Learn how Johnson & Johnson’s 25-year history of innovation is helping eye surgeons meet the moment.

The company’s ability to evolve as it tackles the world’s toughest health challenges has helped Johnson & Johnson earn its spot as the top-ranked healthcare company on the list.

Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer.

The power of partnership, asking questions and speaking up: insights from bladder cancer patients and a caregiver on living with intention after diagnosis.

Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.

Inflammation is the body’s natural response to injury or infection. But when it lingers, inflammation can lead to immune-mediated inflammatory diseases. Learn how Johnson & Johnson is innovating to help bring relief to those living with chronic inflammatory conditions.

This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat immune-mediated diseases such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.